Instructions for Binosto (Alendronic acid) 4 pills
Release form
Pill effervescent
Description:
The tablets are effervescent white or almost white, round, flat, with beveled edges, with a strawberry smell.
1 tab.
alendronate trihydrate sodium (micronized) 91.37 mg,
which is what Alendronic acid is 70 mg
2 pcs. - strips (2) - cardboard packs.
ATC codes
M05BA04 Alendronic acid
Clinical-pharmacological groups / Group affiliation
Bone resorption inhibitor for osteoporosis
Active substance:
alendroic acid
Pharmacotherapy group
Bone resorption inhibitor-bisphosphonate
Pharmacological effect:
Bone resorption inhibitor. Aminobisphosphonate is an analog of pyrophosphate. The mechanism of action is associated with the suppression of osteoclasts. It stimulates osteogenesis, restores positive balance between bone resorption and bone restoration, progressively increases bone mineral density (regulates phosphorus-calcium exchange), promotes the formation of bone tissue with normal histological structure.
Testimony:
Treatment and prevention of osteoporosis in postmenopausal women. Treatment of osteoporosis in men to increase bone mass. Treatment of osteoporosis caused by GCS in men and women. Paget's disease (bone failure) in men and women.
Method of use, course and dosage:
Individual, depending on the readings.
Drug Binosto interaction
The absorption of Alendronic acid is impaired when taken simultaneously with other drugs Binosto and calcium-containing agents.
In postmenopausal women who received estrogens, there were no side effects associated with the use of Alendronic acid.
In clinical studies, there was an increase in the frequency of digestive side reactions when Alendronic acid was administered at a dose of more than 10 mg/day, with acetylsalicylic acid therapy.
Use in pregnancy and breastfeeding
There are no adequate and closely monitored clinical studies on the safety of Alendronic acid in pregnancy and lactation. Breastfeeding should be discontinued if necessary during lactation.
In experimental rat studies, alendron acid at doses of 2 mg/kg/day and above is shown to cause hypocalcemia-induced birth disorderliness; a reduction in the weight of the fruit was observed at doses greater than 5 mg/kg/day.
Side Effect:
On the digestive side: pain in the epigastric area; Rarely - constipation, diarrhea, flatulence, dysphagia.
By metabolism: asymptomatic hypocalcemia.
Dermatological reactions: skin rash, erythema.
Others: headache, myalgia.
Contraindications for use:
Esophageal stricture, achalasia, inability of the patient to stand or sit upright for at least 30 minutes after taking the drug Binosto Binosto, hypocalciemia, increased sensitivity to alendron acid.
Special Instructions:
It is not recommended to use for severe disorders of kidney function, as well as in children.
It is used with caution in cases of gastrointestinal tract diseases in the phase of aggravation.
Patients with mineral metabolism disorders should undergo a complete correction before starting treatment.
The interval between taking Alendronic acid and other preparations should be at least 1 hour.
Application for kidney disorders
It is not recommended to use in cases of severe disorders of kidney function.
Use in children
Use in children is not recommended.
Nosology (ICD codes)
M80.0
Postmenopausal osteoporosis with pathological fracture
M80.1
Osteoporosis with pathological fracture after ovarian removal
M80.4
Drug osteoporosis with pathological fracture
M80.5
Idiopathic osteoporosis with pathological fracture
M80.8
Another osteoporosis with a pathological fracture
M81.0
Postmenopausal osteoporosis
M81.1
Osteoporosis after ovarian removal
M81.4
Drug Binosto osteoporosis
M81.5
Idiopathic osteoporosis
M81.8
Other osteoporosis (senile osteopause)
M88
Paget's disease (bones) [deformative osteitis]
Studies of the use of the drug Binosto in men
Although osteoporosis in men is not as common as in postmenopausal women, a significant proportion of osteoporosis-related fractures occur in men.
The incidence of spinal deformity associated with osteoporosis is similar in men and women. The use of alendronate at a dose of ten mg per day in men for two years reduced the release with urine of cross-linked N-telopeptides of collagen I type by approximately sixty% and bone-specific alkaline phosphatase by approximately 40%.
